British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
- PMID: 32303607
- PMCID: PMC7211081
- DOI: 10.1136/gutjnl-2020-321244
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
Abstract
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
Keywords: crohn's colitis; crohn's disease; ulcerative colitis.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: For details of conflicts of interest see online supplementary table 1.
Comment in
-
Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective.Inflamm Bowel Dis. 2020 Sep 18;26(10):e125-e126. doi: 10.1093/ibd/izaa171. Inflamm Bowel Dis. 2020. PMID: 32592475 Free PMC article. No abstract available.
-
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity.Gut. 2023 Feb;72(2):410-412. doi: 10.1136/gutjnl-2022-327409. Epub 2022 May 5. Gut. 2023. PMID: 35512822 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous